Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.
D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use*; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012673:Semustine / Q000009:adverse effects / Q000627:therapeutic use*; D014226:Triazenes / Q000627:therapeutic use*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D009607:Nitrosourea Compounds; D014226:Triazenes; D012673:Semustine; D014750:Vincristine; D003606:Dacarbazine; D003520:Cyclophosphamide